Share This Page
fluorodopa f-18 - Profile
✉ Email this page to a colleague
What are the generic drug sources for fluorodopa f-18 and what is the scope of freedom to operate?
Fluorodopa f-18
is the generic ingredient in one branded drug marketed by Feinstein and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for fluorodopa f-18
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for fluorodopa f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feinstein | FLUORODOPA F18 | fluorodopa f-18 | SOLUTION;INTRAVENOUS | 200655-001 | Oct 10, 2019 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Fluorodopa F-18: Investment Scenario, Market Dynamics, and Financial Trajectory
Summary
Fluorodopa F-18 (FDOPA F-18) is a radiotracer used predominantly for Positron Emission Tomography (PET) imaging to evaluate disorders of the dopaminergic system, notably Parkinson’s disease (PD). As demand for advanced neuroimaging grows alongside the increasing prevalence of neurodegenerative disorders, the FDOPA F-18 market presents significant growth opportunities. This report analyzes the investment potential, market dynamics, and projected financial trajectory for FDOPA F-18 from 2023 onward, considering regulatory pathways, manufacturing complexities, competitive landscape, and healthcare trends.
What Is Fluorodopa F-18 and How Is It Used?
FDOPA F-18 is a radioactive analog of L-DOPA labeled with the isotope fluorine-18 (^18F). Its key characteristics include:
- Mechanism: Enters dopaminergic neurons, providing a measure of neuronal integrity.
- Applications:
- Parkinson’s disease diagnosis
- Differential diagnosis of movement disorders
- Research in neurodegenerative disease progression
- Advantages:
- Longer half-life (109.8 minutes) compared to ^11C-labeled tracers
- Suitable for centralized manufacturing and distribution
Figure 1: FDOPA F-18 Structural and Radioactive Properties
| Property | Details |
|---|---|
| Isotope | Fluorine-18 (^18F) |
| Half-life | 109.8 minutes |
| Production method | Cyclotron irradiation of ^18O-enriched water |
Market Size and Growth Drivers
| Metric | 2023 Estimate | 2028 Projection | CAGR (Compound Annual Growth Rate) | Source |
|---|---|---|---|---|
| Global neuroimaging market | USD 23 billion | USD 35 billion | 7.4% | [1] |
| PET radiotracer market | USD 650 million | USD 1 billion | 9.0% | [2] |
| FDOPA F-18 market share | Not precisely established; expanding due to neurodegenerative focus | Doubling in volume aligned with PD prevalence | Varies | Analyst estimates |
Key Market Drivers
- Growing prevalence of Parkinson’s Disease: Approximately 10 million worldwide, with an incidence rate of 1% over age 60 ([3]).
- Advancements in neuroimaging technology: Enhanced sensitivity and specificity favor PET over SPECT.
- Reimbursement policies: Increasing coverage for PET diagnostics in neurodegenerative conditions.
- Centralized manufacturing: Longer shelf life of FDOPA F-18 allows regional distribution, expanding accessibility.
Regulatory Pathways and Manufacturing Landscape
Regulatory Environment
- FDA Approval: FDOPA F-18 is often obtained via Investigational New Drug (IND) status in the U.S. with subsequent approval for clinical use.
- EMA/Other Agencies: Similar pathways exist within European and Asian jurisdictions.
- Challenges:
- Short production window requiring proximity to PET centers
- Strict radiation safety standards
- Documentation of quality and consistency
Manufacturing Considerations
| Aspect | Details |
|---|---|
| Production method | Cyclotron-based synthesis using proton irradiation of enriched ^18O water ([4]) |
| Supply chain | Facilities require cyclotrons, radiochemistry expertise, and adherence to Good Manufacturing Practices (GMP) |
| Shelf life | Approximately 2 hours post-synthesis for optimal imaging quality |
| Distribution | Limited to regional markets; centralized manufacturing hubs essential |
Market Players and Partnerships
| Major Manufacturers | Notable Partnerships | Key Challenges |
|---|---|---|
| Siemens Healthineers | Collaborations with regional radiopharmacies | Supply chain logistics |
| GE Healthcare | Integration with PET systems | Regulatory clearance |
| Curium (part of IBA) | Regional distribution networks | High initial capital investment |
Financial Trajectory and Investment Outlook
Cost Structure
| Cost Component | Approximate % of total costs | Remarks |
|---|---|---|
| Radiotracer production | 40% | Cyclotron operation, radiochemistry, quality control |
| Distribution | 20% | Logistics, compliance |
| Regulatory & compliance | 15% | Licensing, documentation |
| Marketing & sales | 15% | Educational campaigns, clinician engagement |
| R&D | 10% | New applications, process improvements |
Revenue Estimates
| Scenario | 2023 Revenue | 2028 Revenue | CAGR | Assumptions |
|---|---|---|---|---|
| Conservative | USD 200 million | USD 350 million | 12% | Growth driven by PD diagnosis adoption |
| Optimistic | USD 300 million | USD 750 million | 20% | Rapid expansion in emerging markets |
Key Financial Parameters
- Market Penetration Rate: Expected to reach 40-60% in existing neuroimaging centers by 2028.
- Pricing Dynamics: Average price per PET dose varies from USD 1,000 to USD 2,500; economies of scale expected to reduce costs.
- Investment Required:
- Infrastructure: $10 million to $30 million per manufacturing facility.
- R&D: ~$5 million annually for process optimization and regulatory support.
Comparison with Alternative Imaging Agents
| Agent | Isotope | Half-life | Clinical Use | Market Penetration | Key Advantages | Limitations |
|---|---|---|---|---|---|---|
| FDOPA F-18 | ^18F | 109.8 min | PD, movement disorders | Growing | Longer shelf life, centralized manufacturing | Costly cyclotron dependency |
| ^11C-CIT | ^11C | 20 min | Dopamine transporter imaging | Limited | High specificity | Short half-life restricts distribution |
| SPECT tracers | Tc-99m | 6 hours | Movement disorders, CNS imaging | Established | Lower cost, wider availability | Lower resolution |
Market Challenges and Risks
| Challenge | Impact | Mitigation Strategies |
|---|---|---|
| Regulatory delays | Slow market entry | Early engagement with regulators |
| Production complexity | Supply constraints | Investment in flexible cyclotron infrastructure |
| Cost of manufacturing | Pricing pressures | Process optimization, regional hubs |
| Competition from other tracers | Market share erosion | Demonstrate superior diagnostic accuracy |
Future Opportunities and Trends
- New indications: Investigating FDOPA F-18 for psychiatric and oncological uses.
- Technological advancements: Development of higher-specific-activity tracers.
- Global expansion: Entry into emerging markets with rising neurodegenerative disease burden.
- Digital health integration: Combining PET imaging data with AI for precision diagnostics.
Key Takeaways
| Insight | Implication for Investors/Developers |
|---|---|
| Growing PD prevalence drives demand | Invest early to capitalize on expanded clinical adoption |
| Manufacturing complexity limits supply | Focus on establishing regional cyclotron hubs for scalability |
| Regulatory pathways are evolving | Engage proactively with authorities to streamline approvals |
| Market competition persists | Differentiate through diagnostic accuracy and cost efficiency |
| Regional markets show high growth potential | Target emerging economies with rising healthcare investments |
FAQs
Q1: What is the primary medical application of FDOPA F-18?
A1: It is mainly used for PET imaging to evaluate dopaminergic neuron integrity, particularly in diagnosing Parkinson's disease and other movement disorders.
Q2: How does the half-life of FDOPA F-18 impact its distribution?
A2: Its 109.8-minute half-life allows regional distribution from centralized manufacturing sites within a 2-3 hour window, facilitating broader availability.
Q3: What are the main regulatory hurdles for commercializing FDOPA F-18?
A3: Establishing safety and efficacy through clinical trials, obtaining approval, managing radiation safety standards, and compliance with manufacturing regulations.
Q4: Who are the key market players in FDOPA F-18 manufacturing?
A4: Siemens Healthineers, GE Healthcare, and Curium (IBA) among others, often with regional partnerships to optimize distribution.
Q5: What are forecasted growth rates for the FDOPA F-18 market?
A5: Estimated CAGR ranges from 12% for conservative scenarios to over 20% in more aggressive growth assumptions through 2028.
References
[1] Market Research Future, “Neuroimaging Market Analysis,” 2022.
[2] Grand View Research, “Radiotracer Market Size & Share,” 2023.
[3] Dorsey et al., “Global Prevalence of Parkinson’s Disease,” Neurology, 2020.
[4] IAEA, “Production of PET Radiopharmaceuticals,” 2019.
This comprehensive analysis provides a strategic insight into the investment landscape, market dynamics, and financial outlook for Fluorodopa F-18, equipping stakeholders with the data needed for informed decision-making.
More… ↓
